《新股消息》華醫網科技申請來港上市
內地醫療衛生人員在線平台華醫網科技申請來港上市,聯席保薦人為美銀及海通國際。
初步招股文件顯示,華醫網科技主要為醫療衛生人員提供數字醫學教育解決方案,向及公眾推出數字健康服務解決方案,以及向醫藥及醫療設備公司提供數字醫療營銷解決方案。
公司於2021年首三季錄收入2.32億元人民幣,按年增長40.5%,期內錄得溢利1,400.3萬元人民幣,對比2020年同期為虧損464.5萬元人民幣。
公司預期,集資所得將用於業務擴張及升級;用於鞏固數字平台及升級AI應用;用於探索戰略合作、投資及收購;及用於營運資金及其他一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.